Corbus Pharmaceuticals Holdings Inc. closed $42.39 short of its 52-week high ($61.90), which the company reached on July 31st ...
Corbus Pharmaceuticals and Novo Nordisk stocks plunge following cannabinoid receptor drug trials, raising concerns over ...
Investor's Business Daily on MSN3h
Novo Dives — And Corbus Crashes — After New Weight-Loss Drug Causes Neuropsychiatric EffectsNovo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.
Why Corbus Pharmaceuticals sees Novo Nordisk’s controversial approach to obesity drugs as a ticket to a blockbuster.
Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose.
Mizuho Securities analyst Graig Suvannavejh has reiterated their bullish stance on CRBP stock, giving a Buy rating on August 28. Graig ...
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private ...
This was the stock's third consecutive day of losses.
As of 8:03 AM GMT+2. Market Open. NORWOOD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback